Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 7Breast Neoplasms 4Multiple Myeloma 2Stomach Neoplasms 1Sarcoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

Cyclophosphamide 72fludarabine 65Tacrolimus 43fludarabine phosphate 40Whole-Body Irradiation 37Mycophenolic Acid 35Busulfan 32Melphalan 28Antilymphocyte Serum 23thymoglobulin 22Thiotepa 20Methotrexate 20Standard of Care 19Stem Cell Transplantation 17Practice Guidelines as Topic 17Granulocyte Colony-Stimulating Factor 17Rituximab 15Surveys and Questionnaires 12Sirolimus 12Filgrastim 12Interviews as Topic 11Cyclosporine 11Blood Specimen Collection 11Peripheral Blood Stem Cell Transplantation 10Exercise 10venetoclax 9Mesna 9Cytarabine 9Bortezomib 9Hematopoietic Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Neoplasms × 1-dodecylpyridoxal × Clear all
NCT00750815 2014-01-20

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
58 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡